Tanvex BioPharma (TPE:6541) E10: NT$-20.71 (As of Dec. 2025)


TPE:6541 Tanvex BioPharma Inc TPE:6541
57 GF Score
Price NT$41.40
GF Value NT$254.61
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Tanvex BioPharma E10?

Tanvex BioPharma TPE:6541 +2.10% 57 E10 is NT$-20.71 as of Dec. 2025. GuruFocus rates TPE:6541 with a GF Score™ of 57/100 and a GF Value™ of NT$254.61 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Tanvex BioPharma's adjusted earnings per share data for the three months ended in Dec. 2025 was NT$-1.600. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is NT$-20.71 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-05), Tanvex BioPharma's current stock price is NT$41.40. Tanvex BioPharma's E10 for the quarter that ended in Dec. 2025 was NT$-20.71. Tanvex BioPharma's Shiller PE Ratio of today is .


Tanvex BioPharma  (TPE:6541) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Tanvex BioPharma E10 Related Terms


Tanvex BioPharma E10 Historical Data

* Premium members only.

The historical data trend for Tanvex BioPharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tanvex BioPharma E10 Chart

Tanvex BioPharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -21.74 -20.71

Tanvex BioPharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.74 -21.66 -21.42 -21.13 -20.71

TPE:6541 vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Tanvex BioPharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tanvex BioPharma Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Tanvex BioPharma's Shiller PE Ratio falls into.


TPE:6541
57GF Score
Tanvex BioPharma Inc TPE:6541
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tanvex BioPharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Tanvex BioPharma's adjusted earnings per share data for the three months ended in Dec. 2025 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=-1.6/324.0540*324.0540
=-1.600

Current CPI (Dec. 2025) = 324.0540.

Tanvex BioPharma Quarterly Data

per share eps CPI Adj_EPS
201603 -2.537 238.132 -3.452
201606 -4.578 241.018 -6.155
201609 -4.275 241.428 -5.738
201612 -6.730 241.432 -9.033
201703 -4.992 243.801 -6.635
201706 -4.965 244.955 -6.568
201709 -4.398 246.819 -5.774
201712 -5.845 246.524 -7.683
201803 -4.231 249.554 -5.494
201806 -8.211 251.989 -10.559
201809 -5.650 252.439 -7.253
201812 -5.246 251.233 -6.767
201903 -5.939 254.202 -7.571
201906 -6.107 256.143 -7.726
201909 -7.900 256.759 -9.971
201912 -6.504 256.974 -8.202
202003 -6.663 258.115 -8.365
202006 -6.062 257.797 -7.620
202009 -4.964 260.280 -6.180
202012 -4.791 260.474 -5.960
202103 -3.839 264.877 -4.697
202106 -3.492 271.696 -4.165
202109 -3.521 274.310 -4.160
202112 -2.800 278.802 -3.254
202203 -2.770 287.504 -3.122
202206 -3.566 296.311 -3.900
202209 -3.379 296.808 -3.689
202212 -3.988 296.797 -4.354
202303 -5.127 301.836 -5.504
202306 -3.858 305.109 -4.098
202309 -3.749 307.789 -3.947
202312 -3.818 306.746 -4.033
202403 -3.094 312.332 -3.210
202406 -2.291 314.175 -2.363
202409 -1.940 315.301 -1.994
202412 -1.650 315.605 -1.694
202503 -2.073 319.799 -2.101
202506 -1.428 322.561 -1.435
202509 -1.080 324.800 -1.078
202512 -1.600 324.054 -1.600

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of NT$-20.71 mean?
Tanvex BioPharma (TPE:6541) has a E10 of NT$-20.71 as of Dec. 2025. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Tanvex BioPharma and its competitors.
Is Tanvex BioPharma's E10 too high?
Tanvex BioPharma's current E10 is NT$-20.71. Overall, Tanvex BioPharma has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's E10 compare to VRTX and REGN?
Tanvex BioPharma's E10 of NT$-20.71 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Tanvex BioPharma and its competitors. Tanvex BioPharma's current E10 is NT$-20.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Tanvex BioPharma (TPE:6541) is currently considered Possible Value Trap. The stock's GF Value™ is NT$254.61, compared to a current price of NT$41.40 — trading 83.7% below its estimated fair value. The current E10 is NT$-20.71. Tanvex BioPharma's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current E10 is NT$-20.71 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tanvex BioPharma (TPE:6541) Overvalued in 2026?

Based on GuruFocus' analysis, Tanvex BioPharma stock appears to be undervalued. The current stock price of NT$41.40 is trading 83.7% below its estimated GF Value™ of NT$254.61. GuruFocus considers Tanvex BioPharma to be Possible Value Trap.

Key valuation signals for TPE:6541:

  • E10: NT$-20.71
  • GF Value™: NT$254.61 vs. price of NT$41.40 (83.7% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the TPE:6541 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tanvex BioPharma Business Description

Address No. 12-2, Shengyi Road, Section 2, 6th Floor, Hsinchu County, Zhubei, TWN, 106
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
57GF Score

Get the complete analysis for TPE:6541

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$41.40
Price
NT$254.61
GF Value